Gamma-aminobutyric acid, or GABA, became one of the central molecules in epilepsy science because it is the brain’s major inhibitory neurotransmitter and a major target of antiseizure treatment.
GABA was not immediately accepted as a neurotransmitter
Early neurochemistry identified GABA in brain tissue before its physiological role was understood.
Experiments in the 1950s linked an inhibitory brain factor to GABA, but its status as a true neurotransmitter was debated for years.
Inhibition becomes central to epilepsy theory
As GABAergic inhibition was established, epilepsy research increasingly framed seizures as disorders of excitation–inhibition balance within neuronal networks.
That concept was more useful than simply describing seizures as uncontrolled electrical activity.
Existing medicines were reinterpreted
Phenobarbital and benzodiazepines were later understood to enhance GABA-A receptor-mediated inhibition.
Their mechanisms helped connect clinical antiseizure effects with receptor biology.
Drug development became more targeted
Once GABA metabolism and transport were understood, therapies could be designed to increase GABA availability or prolong its action.
Vigabatrin inhibits GABA transaminase, while tiagabine inhibits GABA reuptake.
GABA is more complicated than an ‘off switch’
Modern research shows many GABA receptor subtypes, synaptic and extrasynaptic signalling, and developmental changes in chloride gradients.
In some pathological contexts, GABAergic signalling can behave in ways that are not simply inhibitory.
The historical importance
The discovery of GABA helped move epilepsy pharmacology from empirical drug effects toward mechanistic neuroscience.
It remains one of the clearest examples of how basic neurochemistry changed seizure treatment.
Related reading
Sources and further reading
- GABA: history and perspectives
- GABAA receptor neurotransmission and epilepsy
- The GABA synapse as a target for antiepileptic drugs
Evidence checked: September 2026.